Archive for August, 2008

Spectrum Pharmaceuticals - Investor Conference Overview

August 19th, 2008

Spectrum Pharmaceutical’s CEO Rajesh Shrotriya, M.D presented an overview of the company today in Las Vegas at the Noble Financial Conference. I wanted to view the presentation in order to see if I could get additional information that may have been overlooked during my previous reviews of this company. For those of you who haven’t [...]

Continue reading ... Posted in Biotech companies | tagged

A.P. Pharma (APPA) Investment Profile

August 16th, 2008

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and central nervous system (CNS) therapy markets, and is currently experiencing strong growth. Analysts predict that the sector will grow to $60 billion by 2010. The frequency and debilitating nature of chemotherapeutic side-effects are a huge problem that requires the discovery and development [...]

Continue reading ... Posted in Biotech companies | tagged

Spectrum Pharmaceuticals’ Pipeline

August 14th, 2008

Let’s continue with our analysis of Spectrum Pharmaceuticals (SPPI), specifically reviewing their pipeline of drugs in development for readers that are interested in biotech stock investing.
Levoleucovorin (Fusilev):
Fusilev was approved in March 2008 as rescue therapy for osteosarcoma patients after receiving high-dose methotrexate (chemotherapy). Osteosarcoma is a malignant bone cancer afflicting individuals under the age of [...]

Continue reading ... Posted in Biotech companies | tagged

Spectrum Pharmaceuticals Investment Profile

August 10th, 2008

Spectrum Pharmaceuticals (SPPI) is a small cap biotech company that focuses on developing drugs in oncology and urology. Spectrum fits my investment criteria and warrants a thorough analysis. The company currently trades at a technology value (see previous posts on tech value) lower than any company I’ve come across over the past 8 years. In [...]

Continue reading ... Posted in Biotech companies | tagged

Another Biotech Acquired - Imclone

August 1st, 2008

Bristol-Myers Squibb made an offer today to purchase Imclone Systems for $60 per share or $4.5 billion in cash. Bristol already owns about 17 percent of Imclone so today’s offer values Imclone at $5.2 billion.
The offer was a 30 percent premium over Wednesday’s closing price of $46.44 per share. Shares of Imclone closed at $63.93, [...]

Continue reading ... Posted in Biotech companies, Biotech general | tagged